Inozyme Pharma (NASDAQ:INZY) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Inozyme Pharma (NASDAQ:INZY) announced its quarterly earnings data on Tuesday. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05, Zacks reports.

Inozyme Pharma Trading Down 0.2 %

Shares of INZY stock traded down $0.01 during trading hours on Friday, reaching $4.09. 113,840 shares of the stock were exchanged, compared to its average volume of 417,247. Inozyme Pharma has a 12-month low of $2.71 and a 12-month high of $7.80. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $5.13 and its 200-day moving average price is $4.92. The firm has a market capitalization of $256.57 million, a price-to-earnings ratio of -2.81 and a beta of 1.54.

Wall Street Analyst Weigh In

INZY has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Stifel Nicolaus initiated coverage on shares of Inozyme Pharma in a research note on Thursday, September 12th. They set a “buy” rating and a $16.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research note on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Inozyme Pharma presently has an average rating of “Buy” and a consensus target price of $15.71.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.